GlassScriptPhysician profile
Jessica A Ward
NPI 1730370800
$6,323.56
in general payments reported to CMS, 2019-2025
43 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $242 · 2021: $583 · 2022: $1,235 · 2023: $1,382 · 2024: $1,230 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,620 · Education: $25.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,619.67 |
| Education | $25.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,301.60 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $1,004.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $768.67 | 2019-2025 | Mounjaro, Zepbound, Amyvid |
| Glaxosmithkline, LLC. | $430.89 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.91 | 2019-2024 | Jardiance, Synjardy, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $264.98 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $228.48 | 2019-2025 | Repatha, Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $167.79 | 2019-2025 | Eliquis |
| Pfizer INC. | $162.84 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $130.42 | 2020-2024 | Xarelto |
| Astellas Pharma US INC | $121.48 | 2021-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $98.78 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $92.98 | 2019-2023 | Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $85.56 | 2023-2025 | Rexulti |
| Shield Therapeutics INC | $78.30 | 2023-2025 | Accrufer |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.